FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to prodrug compositions based on hydrogel. The cross-linked HA hydrogel-drug conjugate contains a number of hyaluronic acid polymers with a number of linearly connected units of a specific structure, the drug being a fragment of an anti-VEGF antibody. Also the following is disclosed: a pharmaceutical composition, the use of a pharmaceutical composition as a drug for the production of a drug for treating a disorder associated with pathological angiogenesis in a subject, for reducing or inhibiting angiogenesis in a subject with a disorder associated with pathological angiogenesis, for treating a disorder associated with pathological angiogenesis, in a subject, a method of treating an ophthalmic disease.
EFFECT: group of inventions ensures the release of a drug under physiological conditions.
27 cl, 15 dwg, 8 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| OPTIMIZED ANTIBODY COMPOSITIONS FOR TREATMENT OF EYE DISEASES | 2018 |
|
RU2782355C2 |
| ANTIBODIES AGAINST HtrA1 AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2750285C2 |
| HUMANISED HUMAN CD19 ANTIBODIES AND METHODS FOR USE THEREOF | 2016 |
|
RU2731156C1 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
| HUMANIZED ANTIBODIES AND ANTIBODIES WITH MATURE AFFINITY AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2748943C2 |
| ANTI-HLA-G ANTIBODIES AND THEIR USE | 2019 |
|
RU2797724C2 |
| ANTI-FcRH5 ANTIBODIES | 2014 |
|
RU2687132C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
